When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

In healthy adults, a single low dose of IMP761 continues to be safe and appears to reduce the activity of T-cells, a clinical ...

A new study by researchers in the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential drug targets for the treatment of multiple sclerosis. The study may pave the ...